| Literature DB >> 33621434 |
Michael J Booth1, Daniel Clauw1, Mary R Janevic1, Lindsay C Kobayashi1, John D Piette2.
Abstract
OBJECTIVE: To determine the validity of self-reported physician diagnosis of rheumatoid arthritis (RA) using multiple gold-standard measures based on Medicare claims in a nationally representative sample of older adults and to verify whether additional questions about taking medication and having seen a physician in the past two years for arthritis can improve the positive predictive value (PPV) and other measures of the validity of self-reported RA.Entities:
Year: 2021 PMID: 33621434 PMCID: PMC8063145 DOI: 10.1002/acr2.11229
Source DB: PubMed Journal: ACR Open Rheumatol ISSN: 2578-5745
Figure 1Contingency table calculations.
Validation studies of self‐reported RA
| Author, Year | Data Source | Study Type | Population | Gold Standard | Results |
|---|---|---|---|---|---|
| O’Rourke et al, 2019 | Collected at time of survey | Online self‐report questionnaire (Massachusetts) | Adult patients of a primary care clinic aged 18‐70 yr | Electronic medical record review | PPV = 32%; sensitivity = 54% |
| Videm et al, 2017 | Nord‐Trøndelag Health Study | Population‐based cohort study | Inhabitants of Nord‐Trøndelag aged 20 yr and older | Hospital case files using EULAR 2010 criteria reviewed by immunologist | PPV = 19% |
| Formica et al, 2010 | Black Women's Health Study | Prospective cohort study (United States) | Black women aged 21‐69 yr | Medical Record and physician checklist review by blinded Rheumatologist. | No medication PPV = 29%; NSAID PPV = 61%; DMARD PPV = 76% |
| Oksanen et al, 2010 | Finnish Public Sector Study | Prospective survey (Finland) | Employees of participating organizations | Clinical diagnosis of treating physician derived from three national registries. | PPV = 33%; sensitivity = 83%; κ = 0.47 |
| Cooper et al, 2008 | Canadian Network for Improved Outcomes in SLE | Clinic‐based questionnaire (Canada) | Probands of SLE recruited from 11 rheumatology clinics | Medical record review | PPV = 25% |
| Walitt et al, 2008 | Women's Health Initiative | Prospective cohort study (United States) | Postmenopausal women aged 50‐79 yr | Medical records reviewed by three blinded rheumatologists. | PPV = 14.7%; sensitivity = 100%; κ = 0.06; DMARD PPV = 62.2%; DMARD sensitivity = 54.8%; DMARD κ = 0.53 |
| Karlson et al, 2004 | Longitudinal Nurses’ Health Study | Prospective cohort study (United States) | Female nurses aged 30‐55 yr | Medical record review by two rheumatologists using ACR criteria | PPV = 29% |
| Mikuls, et al, 2002 | Iowa Women's Health Study | Prospective cohort study (United States) | Women aged 55‐69 yr in the state of Iowa | Medical record review by a combination of two trained rheumatologists, rheumatology advanced practice nurses, or rheumatology physician assistants using ACR criteria | PPV = 13% |
| Ling et al, 2000 | Women's Health and Aging Study | Prospective cohort study (United States) | Community‐dwelling disabled women aged 65 yr and older | Algorithm based on ACR criteria | PPV = 34%; sensitivity = 77%; κ = 0.46 |
| Karlson et al, 1999 | Women's Health Cohort Study | Prospective cohort study (United States) | Female health professionals aged 45 yr and older | Medical records reviewed by two board certified rheumatologists | PPV = 35.8% |
| Kvien et al, 1996 | Collected at time of survey | Postal survey (Norway) | Randomly selected individuals of Oslo, Norway, aged 20‐79 7r | Clinical examination and Oslo RA registry | PPV = 31% |
| Star et al, 1996 | Study of Osteoporotic Fractures | Prospective cohort study (United States) | Caucasian women aged 65 yr and older from Maryland. | Physician submitted survey of ACR criteria (1987), medical records, and radiographic hand features of RA, reviewed by investigators | PPV = 21% |
| Rasooly et al, 1995 | Collected at time of survey | Mailed survey (England) | Rheumatology outpatients from Manchester Royal Infirmary | Recorded ICD‐9 clinical diagnostic codes from clinic registry | Sensitivity = 90% |
ACR, American College of Rheumatology; DMARD, disease‐modifying antirheumatic drug; EULAR, European League Against Rheumatism; NSAID, nonsteroidal anti‐inflammatory drug; PPV, positive predictive value; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
Figure 2Study sample flow chart.
Population characteristics of incident self‐reported RA and Medicare claims history from the HRS, 2004‐2012
| Population Characteristic (n = 3768) | Incident Self‐Reported RA | One or More Medicare RA Claims | Two or More Medicare RA Claims | Two or More Medicare RA Claims, One by a Rheumatologist | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative (n = 3423) | Positive (n = 345) |
| Negative (n = 3523) | Positive (n = 245) |
| Negative (n = 3655) | Positive (n = 103) |
| Negative (n = 3739) | Positive (n = 29) |
| |
| Age in 2004, mean (SD), yr | 73.7 (6.7) | 73.5 (6.5) | 0.59 | 73.7 (6.7) | 73.5 (6.4) | 0.69 | 73.7 (6.7) | 72.8 (5.7) | 0.09 | 73.7 (6.7) | 71.1 (5.0) | 0.038* |
| Sex, n (%) | ||||||||||||
| Male | 1412 (41.3) | 140 (40.6) | 0.81 | 1480 (42.0) | 72 (29.4) | <0.001* | 1524 (41.6) | 28 (27.2) | 0.003* | 1544 (41.3) | 8 (27.6) | 0.14 |
| Female | 2011 (58.7) | 205 (59.4) | 2043 (58.0) | 173 (70.6) | 2141 (58.4) | 75 (72.8) | 2195 (58.7) | 21 (72.4) | ||||
| Race and ethnicity | ||||||||||||
| Non‐Hispanic White | 3056 (89.3) | 280 (81.2) | <0.001* | 3124 (88.7) | 212 (86.5) | 0.34 | 3,243 (88.5) | 93 (90.3) | 0.59 | 3,309 (88.5) | Omitted | 0.56 |
| Black/African American | 283 (8.3) | 54 (15.6) | 309 (8.8) | 28 (11.4) | 328 (8.9) | Omitted | 336 (9.0) | Omitted | ||||
| Other | 84 (2.4) | 11 (3.2) | 90 (2.6) | 5 (2.0) | 94 (2.6) | Omitted | 94 (2.5) | Omitted | ||||
| Education | ||||||||||||
| Less than high school | 641 (18.7%) | 102 (29.6%) | <0.001* | 676 (19.2) | 67 (27.4) | 0.005* | 721 (19.7) | 22 (21.4) | 0.64 | 737 (19.7) | 6 (20.7) | 0.71 |
| High school or equivalent | 1899 (55.5) | 192 (55.7) | 1957 (55.6) | 134 (54.7) | 2030 (55.4) | 61 (59.2) | 2073 (55.4) | 18 (62.1) | ||||
| 2‐yr college | 109 (3.2) | 4 (1.2) | 107 (3.0) | 6 (2.5) | 111 (3.0) | Omitted | 113 (3.0) | Omitted | ||||
| 4‐yr college or more | 774 (22.6) | 47 (13.6) | 783 (22.2) | 38 (15.5) | 803 (21.9) | Omitted | 816 (21.8) | Omitted | ||||
| Household wealth, n (%) | ||||||||||||
| <25th percentile | 815 (23.8) | 133 (38.6) | <0.001* | 870 (24.7) | 78 (31.8) | 0.04* | 913 (24.9) | 35 (34.0) | 0.07 | 940 (25.1) | 8 (27.6) | 0.14 |
| 25th‐50th percentile | 849 (24.8) | 87 (25.2) | 872 (24.8) | 64 (26.1%) | 910 (24.8%) | 26 (25.2%) | 927 (24.8%) | Omitted | ||||
| 50th‐75th percentile | 873 (25.5) |
|
|
|
|
|
| Omitted | ||||
| 75th‐99th percentile |
|
|
|
|
|
|
|
| ||||
HRS, Health and Retirement Study; RA, rheumatoid arthritis.
* Denotes statistically significant P value at 0.05α.
Omitted rows are not reported because of low cell counts and HRS policy that protects the confidentiality of respondents.
Continuous measures were tested with a t test of equal or unequal variance as appropriate. Categorical measures were tested using Pearson's χ2.
Sociodemographic Characteristics of HRS Respondents Age 65+ with and without Medicare linkage and with and without full FFS Parts A and B coverage
| Population Characteristic | Medicare Linkage | Full Parts A and B FFS Coverage for Either Reference Period | ||||
|---|---|---|---|---|---|---|
| No (n = 721) | Yes (n = 10 374) |
| No (n = 4791) | Yes (n = 5583) |
| |
| Self‐reported RA in 2004, n (%) | ||||||
| No | 554 (6.8) | 7634 (93.2) | 0.16 | 3457 (45.3) | 4177 (54.7) | 0.005* |
| Yes | 77 (5.9) | 1236 (94.1) | 616 (49.8) | 620 (50.2) | ||
| Do not know | 90 (5.7) | 1503 (94.3) | 718 (47.8) | 785 (52.2) | ||
| Age in 2004, mean (SD), yr | 74 (8.3) | 75 (7.5) | 0.002* | 76.3 (8.2) | 73.8 (6.7) | <0.001* |
| Sex (n, %) | ||||||
| Male | 349 (7.4) | 4372 (92.6) | 0.001* | 2097 (48.0) | 2275 (52.0) | 0.002* |
| Female | 372 (5.8) | 6002 (94.2) | 2694 (44.9) | 3308 (55.1) | ||
| Race and ethnicity, n (%) | ||||||
| Non‐Hispanic White | 563 (6.1) | 8709 (93.9) | <0.001* | 3900 (44.8) | 4809 (55.2) | <0.001* |
| Black/African American | 129 (8.8) | 1342 (91.2) | 726 (54.1) | 616 (45.9) | ||
| Other | 29 (8.3) | 322 (91.7) | 164 (50.9) | 158 (49.1) | ||
| Education, n (%) | ||||||
| Less than high school | 228 (7.2) | 2960 (92.8) | 0.31 | 1637 (55.3) | 1323 (44.7) | <0.001* |
| High school or equivalent | 354 (6.2) | 5,405 (93.8) | 2356 (43.6) | 3049 (56.4%) | ||
| 2‐yr college | 22 (7.0) | 292 (93.0) | 140 (48.0) | 152 (52.0) | ||
| 4‐yr college or more | 117 (6.4) | 1717 (93.6) | 658 (38.3) | 1059 (61.7) | ||
| Total household wealth, n (%) | ||||||
| <25th percentile | 210 (7.6) | 2567 (92.4) | 0.03* | 1481 (57.1) | 1,113 (42.9) | <0.001* |
| 25‐50th percentile | 184 (6.6) | 2595 (93.4) | 1261 (48.6) | 1,334 (51.4) | ||
| 50‐75th percentile | 158 (5.7) | 2608 (94.3) | 1109 (42.8) | 1,484 (57.2) | ||
| 75th‐99th percentile | 169 (6.1) | 2604 (93.9) | 940 (36.3) | 1,652 (63.7) | ||
FFS, fee for service; HRS, Health and Retirement Study; RA, rheumatoid arthritis.
* Denotes statistically significant P value at 0.05 α.
Self‐reported RA validation with Medicare claims, 2004‐2012
| Self‐Reported RA (n = 345) | Self‐Reported RA + RX (n = 161) | Self‐Reported RA + Doctor (n = 152) | Self‐Reported RA + RX + Doctor (n = 111) | |
|---|---|---|---|---|
| CDC method: one or more RA claims | ||||
| Sensitivity | 0.23 | 0.18 | 0.18 | 0.15 |
| Specificity | 0.92 | 0.97 | 0.97 | 0.98 |
| PPV | 0.16 | 0.27 | 0.29 | 0.33 |
| NPV | 0.95 | 0.94 | 0.94 | 0.94 |
| κ | 0.13 | 0.17 | 0.18 | 0.17 |
| CCW method: two or more RA claims | ||||
| Sensitivity | 0.40 | 0.43 | 0.31 | 0.26 |
| Specificity | 0.92 | 0.96 | 0.97 | 0.98 |
| PPV | 0.12 | 0.19 | 0.21 | 0.24 |
| NPV | 0.98 | 0.98 | 0.98 | 0.98 |
| κ | 0.15 | 0.20 | 0.23 | 0.23 |
| Strict method: two or more RA claims, one from a rheumatologist | ||||
| Sensitivity | 0.55 | 0.45 | 0.55 | 0.45 |
| Specificity | 0.91 | 0.96 | 0.96 | 0.97 |
| PPV | 0.05 | 0.08 | 0.11 | 0.12 |
| NPV | 0.99 | 0.99 | 0.99 | 0.99 |
| κ | 0.07 | 0.12 | 0.23 | 0.18 |
CCW, Chronic Conditions Warehouse; CDC, Centers for Disease Control and Prevention; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis.
RX = Self‐report that respondent is taking medication for arthritis. Doctor = Self‐report the respondent has seen a doctor in the past two years for arthritis. Sensitivity is the proportion of people with a Medicare history of RA reporting that they have RA. Specificity is the proportion of people without a Medicare history of RA of all respondents not reporting RA. The NPV is the proportion of respondents not reporting RA who have no Medicare history of RA. The CDC method is the CDC case definition of a single RA diagnosis. The CCW method is the CCW criteria of two RA diagnoses no greater than 2 years apart. The strict method is a minimum of two RA claims no more than 2 years apart, with a minimum of one claim from a rheumatologist.